N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications

References

• G Aldini, M Carini, G Beretta, S Bradamante, and RM Facino. (2002a). Carnosine is a quencher of 4-hydroxy-nonenal: Through what mechanism of reaction?. Biochem Biophys Res Commun 298 (5):699–706.
   PubMed Web of Science ®Google Scholar
• G Aldini, P Granata, and M Carini. (2002b). Detoxification of cytotoxic alpha,beta-unsaturated aldehydes by carnosine: Characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrom 37 (12):1219–1228.
   PubMed Web of Science ®Google Scholar
• E Altomare, I Grattagliano, G Vendemaile, T Micelli-Ferrari, A Signorile, and L Cardia. (1997). Oxidative protein damage in human diabetic eye: Evidence of a retinal participation. Eur J Clin Invest 27 (2):141–147.
   PubMed Web of Science ®Google Scholar
• Anonymous. (2000). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381–389.
   PubMedGoogle Scholar
• NH Ansari, L Wang, AA Erwin, and DF Church. (1996a). Glucose-dependent formation of free radical species in lens homogenate. Biochem Mol Med 59 (1):68–71.
   PubMedGoogle Scholar
• NH Ansari, L Wang, and SK Srivastava. (1996b). Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract. Biochem Mol Med 58 (1):25–30.
   PubMedGoogle Scholar
• MA Babizhayev. (1989). Antioxidant activity of l-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta 1004:363–371.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev. (1996). Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim Biophys Acta 1315:87–99.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev. (2003). Glare disability and driving safety. Ophthalmic Res 35 (1):19–25.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev. (2004a). Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res 7:186–198.
   PubMed Web of Science ®Google Scholar
• MA. Babizhayev 2004b. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO2004/028536 A1. International Publication Date: 8 April 2004.
   Google Scholar
• MA Babizhayev. (2006). Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol 1 (3):201–233.
   Google Scholar
• MA Babizhayev. 1993. Composizioni farmaceutiche contenenti N-acetilcarnosina per il trattamento della cataratta. Italian Patent A61K gruppo 37/00 20122 MI, Priority Oct. 15, 1993.
   Google Scholar
• MA Babizhayev, and E Bozzo Costa. (1994a). Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim Biophys Acta 1225:326–337.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev E Bozzo Costa1994b. Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract. Patent PCT/EP 94/03340 SCB 238 PCT, Oct. 10, 1994.
   Google Scholar
• MA Babizhayev, and AI Deyev. (1986). Free radical oxidation of lipids and thiol groups in the formation of a cataract. Biofizika 31 (1):109–114.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev, and AI Deyev. (1989). Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta 1004 (1):124–133.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev, AI Deyev, and LF Linberg. (1988). Lipid peroxidation as a possible cause of cataract. Mech Ageing Dev 44 (1):69–89.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev, AI Deyev, VN Yermakova, IV Brikman, and J Bours. (2004). Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs in Research & Development 5 (3):125–139.
   Google Scholar
• MA Babizhayev, AI Deyev, VN Yermakova, NG Davydova, NI Kurysheva, VS Doroshenko, and AV Zhukotskii. (2003). Image analysis and glare sensitivity in human age-related cataracts. Clin Exp Optom 86 (3):157–172.
   PubMedGoogle Scholar
• MA Babizhayev, AI Deyev, VN Yermakova, VV Remenschikov, and J Bours. (2006). Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther 1:91–116.
   Google Scholar
• MA Babizhayev, AI Deyev, VN Yermakova, YA Semiletov, NG Davydova, VS Doroshenko, AV Zhukotskii, and IM Goldman. (2002). Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs in Research & Development 3 (2):87–103.
   Google Scholar
• MA Babizhayev, AI Deyev, VN Yermakova, YuA Semiletov, NG Davydova, NI Kurysheva, AV Zhukotskii, and IM Goldman. (2001). N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 22:979–994.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev, K Meguro. Combined use of carnosinase inhibitor with l-carnosines and composition. WO 2004/064866 PCT/JP2004/000351. Filed 20 January 2003 (20.01.2003).
   Google Scholar
• MA. Babizhayev M-C.Seguin 1999. Process of assessment of ocular dysfunctions and implementation devices of this process. US Patent No. 6,007,203. Date of patent: December 28, 1999.
   Google Scholar
• MA Babizhayev, M-C Seguin, J Gueyne, RP Evstigneeva, EA Ageyeva, and GA Zheltukhina. (1994). l-Carnosine (β-alanyl-L-histidine) and carcinine (β -alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid peroxidase activities. Biochem J 304:509–516.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev, VN Yermakova, AI Deyev, and M-C Seguin. (2000). Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. Journal of Anti-Aging Medicine 3:43–62.
   Google Scholar
• MA Babizhayev, VN Yermakova, NL Sakina, RP Evstigneeva, EA Rozhkova, and GA Zheltukhina. (1996). N-acetylcarnosine is a prodrug of l-carnosine in ophthalmic application as antioxidant. Clin Chim Acta 254:1–21.
   PubMed Web of Science ®Google Scholar
• MA Babizhayev, VN Yermakova, YuA Semiletov, and AI Deyev. (2000). The natural histidine-containing dipeptide N-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Moscow) 65:588–598.
   PubMed Web of Science ®Google Scholar
• JW Baynes. (2003). Chemical modification of proteins by lipids in diabetes. Clin Chem Lab Med 41 (9):1159–1165.
   PubMed Web of Science ®Google Scholar
• AA Boldyrev, AM Dupin, AYa Bunin, MA Babizhayev, and SE Severin. (1987). The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int 15:1105–1113.
   PubMedGoogle Scholar
• G Brian, and HR Taylor. (2001). Cataract blindness: Challenge for the 21st century. Bulleten of World Health Organization 79:249–256.
   PubMed Web of Science ®Google Scholar
• M Brownlee. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820.
   PubMed Web of Science ®Google Scholar
• C Brownson, and AR Hipkiss. (2000). Carnosine reacts with a glycated protein. Free Radic Biol Med 28 (10):1564–1570.
   PubMed Web of Science ®Google Scholar
• HF Bunn. (1981). Non-enzymatic glycosylation of protein: A form of molecular aging. Schweiz Med Wochenschr 111 (41):1503–1507.
   PubMedGoogle Scholar
• DL Cohen, HA Neil, J Sparrow, M Thorogood, and JI Mann. (1990). Lens opacity and mortality in diabetes. Diabet Med 7 (7):615–617.
   PubMed Web of Science ®Google Scholar
• PL Colsher, and RB Wallace. (1993). Geriatric assessment and driver functioning. Clin Geriatr Med 9:365–375.
   PubMedGoogle Scholar
• DB Elliott, and MA Bullimore. (1993). Assessing the reliability, discriminative ability, and validity of disability glare tests. Invest Ophthalmol Vis Sci 34:108–119.
   PubMed Web of Science ®Google Scholar
• FL FerrisIII, A Kassoff, GH Bresnick, and I Bailey. (1982). New visual acuity charts for clinical research. Am J Ophthalmol 94:91–96.
   PubMed Web of Science ®Google Scholar
• FL Ferris, and RD Sperduto. (1982). Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol 94:97–98.
   PubMed Web of Science ®Google Scholar
• DC Gritz. (2001). Can cataracts be prevented?. Bulleten of World Health Organization 79:260–261.
   PubMed Web of Science ®Google Scholar
• A Guiotto, P Ruzza, MA Babizhayev, and A Calderan. (2007). Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem 15 (18):6158–6163. Epub 2007 June 20
   PubMed Web of Science ®Google Scholar
• AR Hipkiss. (2005). Glycation, ageing and carnosine: Are carnivorous diets beneficial?. Mech Ageing Dev 126 (10):1034–1039.
   PubMed Web of Science ®Google Scholar
• AR Hipkiss, C Brownson, MF Bertani, E Ruiz, and A Ferro. (2002). Reaction of carnosine with aged proteins: Another protective process?. Ann N Y Acad Sci 959:285–294.
   PubMed Web of Science ®Google Scholar
• AR Hipkiss, and H Chana. (1998). Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 248 (1):28–32.
   PubMed Web of Science ®Google Scholar
• AR Hipkiss, J Michaelis, and P Syrris. (1995). Non-enzymatic glycosylation of the dipeptide l-carnosine, a potential anti-protein-cross-linking agent. Federation of European Biochemical Society Letters 371 (1):81–85.
   PubMed Web of Science ®Google Scholar
• AR Hipkiss, J Michaelis, P Syrris, S Kumar, and Y Lam. (1994). Carnosine protects proteins against in vitro glycation and cross-linking. Biochem Soc Trans 22 (4):399S.
   PubMed Web of Science ®Google Scholar
• AR Hipkiss, JE Preston, DT Himswoth, VC Worthington, and NJ Abbot. (1997). Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett 238 (3):135–138.
   PubMed Web of Science ®Google Scholar
• AR Hipkiss, VC Worthington, DT Himsworth, and W Herwig. (1998). Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim Biophys Acta 1380 (1):46–54.
   PubMed Web of Science ®Google Scholar
• LJ Hobart, I Seibel, GS Yeargans, and NW Seidler. (2004). Anti-crosslinking properties of carnosine: Significance of histidine. Life Sci 75:1379–1389.
   PubMed Web of Science ®Google Scholar
• AS Januszewski, NL Alderson, TO Metz, SR Thorpe, and JW Baynes. (2003). Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31 (Pt 6):1413–1416.
   PubMedGoogle Scholar
• JH Kang, KS Kim, SY Choi, HY Kwon, MH Won, and TC Kang. (2002). Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu,Zn-superoxide dismutase modification. Biochim Biophys Acta 1570:89–96.
   PubMed Web of Science ®Google Scholar
• R Klein, BE Klein, SE Moss, and KJ Cruickshanks. (1999). Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 117 (11):1487–1495.
   PubMed Web of Science ®Google Scholar
• C Kupfer. (1984). The conquest of cataract, a global challenge. Trans Ophthalmol Soc UK 104:1–10.
   Google Scholar
• C Kupfer, B Underwood, and T Gillen. (1994). Leading causes of visual impairment worldwide. In: DM Albert, FA Jakobiec, editors. Principles and practice of ophthalmology. Basic sciences. Philadelphia, PA: W.B. Saunders & Co. p 1249–1255.
   Google Scholar
• DC Minassian, V Mehra, and GJ Johnson. (1992). Mortality and cataract: Findings from a population-based longitudinal study. Bull World Health Organ 70 (2):219–223.
   PubMed Web of Science ®Google Scholar
• K Murakami, JH Jahngen, SW Lin, KJ Davies, and A Taylor. (1990). Lens proteasome shows enhanced rates of degradation of hydroxyl radical modified alpha-crystallin. Free Radic Biol Med 8:217–222.
   PubMed Web of Science ®Google Scholar
• KO Muranov, AK Dizhevskaia, AA Boldyrev, OE Karpova, NL Sheremet, GS Polunin, and SE Avetisov. (2008). [Search for chaperon-like anticataract drugs, the antiaggregants of lens crystallins. Communication. 1. Chaperon-like activity of N-acetyl carnosine dipeptide: In vitro study on a model of ultraviolet-induced aggregation of betaL-crystallin]. Vestn Oftalmol 124 (2):3–6. Ostrovski MA
   PubMedGoogle Scholar
• J O'Brien, HE, Nursten, MJC, Crabbe, JM Ames 1997. The Maillard Reaction in Foods and Medicine. The Royal Society of Chemistry, The 6th International Symposium on the Maillard Reaction. London, UK, 27-30 July 1997.
   Google Scholar
• T Okamoto, S Tanaka, AC Stan, T Koike, M Kase, Z Makita, H Sawa, and K Nagashima. (2002). Advanced glycation end products induce angiogenesis in vivo. Microvasc Res 63 (2):186–195.
   PubMed Web of Science ®Google Scholar
• C Owsley, BT Stalvey, J Wells, ME Sloane, and G McGwinJr.. (2001). Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol 119:881–887.
   PubMed Web of Science ®Google Scholar
• DI Price, PM Rhett, SR Thorpe, and JW Baynes. (2001). Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 276:48967–48972.
   PubMed Web of Science ®Google Scholar
• NW Seidler, GS Yeargans, and TG Morgan. (2004). Carnosine disaggregates glycated alpha-crystallin: An in vitro study. Arch Biochem Biophys 427:110–115.
   PubMed Web of Science ®Google Scholar
• H Sugimura, I Horiguchi, T Shimizu, and E Marui. (2007). Relationship between employees' management factor of visual display terminal (VDT) work time and 28-item General Health Questionnaire (GHQ-28) at one Japanese IT company's computer worksite. Nippon Eiseigaku Zasshi 62 (4):960–966.
   PubMedGoogle Scholar
• BS Szwergold. (2005a). Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun 336 (1):36–41.
   PubMed Web of Science ®Google Scholar
• BS Szwergold. (2005b). Intrinsic toxicity of glucose, due to non-enzymatic glycation, is controlled in-vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines. Med Hypotheses 65:337–348.
   PubMed Web of Science ®Google Scholar
• A Taylor, and KJ Davies. (1987). Protein oxidation and loss of protease activity may lead to cataract formation in the aged lens. Free Radic Biol Med 3:371–377.
   PubMed Web of Science ®Google Scholar
• RC Turner, CA Cull, V Frighi, and RR Holman. (1999). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 281:2005–2012.
   PubMed Web of Science ®Google Scholar
• H Ukeda, Y Hasegawa, Y Harada, and M Sawamura. (2002). Effect of carnosine and related compounds on the inactivation of human Cu,Zn- superoxide dismutase by modification of fructose and glycolaldehyde. Biosci Biotechnol Biochem 66 (1):36–43.
   PubMed Web of Science ®Google Scholar
• TJTP Van den Berg. (1986). Importance of pathological intraocular light scatter for visual disability. Doc Ophthalmol 61:327–333.
   PubMed Web of Science ®Google Scholar
• Vision Research. 1998. A National Plan 1999–2002. Report of the National Advisory Council, National Eye Institute. p 59.
   Google Scholar
• SK West. (2000). Looking forward to 20/20: A focus on the epidemiology of eye diseases. Epidemiol Rev 22:64–70.
   PubMed Web of Science ®Google Scholar
• IS Wright. (1987). Keeping an eye on the rest of the body. Ophthalmology 94:1196–1198.
   PubMed Web of Science ®Google Scholar
• S-I Yamagishi, K Nakamura, and T Imaizumi. (2005). Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diab Rev 1:93–106.
   PubMedGoogle Scholar
• T Yu, JL Robotham, and Y Yoon. (2006). Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 103 (8):2653–2658. Epub 2006 Feb 13
   PubMed Web of Science ®Google Scholar
• S Zhou, and EA Decker. (1999). Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J Agric Food Chem 47 (1):51–55.
   PubMed Web of Science ®Google Scholar